Paritaprevir (formerly ABT-450) was identified as a lead compound by AbbVie and Enanta Pharmaceuticals.
Platelet count, mean × 10 9 /L ± SD 78.4 ± 15.3 77.5 ± 13.0 120.0 ± 79.0 119.9 ± 49.8
Serum albumin, mean g/dL ± SD 3.76 ± 0.39 3.68 ± 0.39 3.23 ± 0.15 3.18 ± 0.21
Values are n (%) unless otherwise specified. 1.99 *Patient discontinued due to study drug non-compliance and was subsequently lost to follow-up. †Patient discontinued due to a serious event of chronic obstructive pulmonary disease and subsequently relapsed. SVR12, sustained virologic response at post-treatment week 12; Pt, patient; Tx, treatment; HCV, hepatitis C virus; GT, genotype; BMI, body mass index; AFP, alpha-fetoprotein. 
